{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:32:39Z","timestamp":1794979959303,"version":"4.9.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.drugalcdep.2020.108147","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T11:57:02Z","timestamp":1593691022000},"page":"108147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"special_numbering":"C","title":["Protracted renal clearance of fentanyl in persons with opioid use disorder"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-7701","authenticated-orcid":false,"given":"Andrew S.","family":"Huhn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Gregory","family":"Hobelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Oyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8482-5461","authenticated-orcid":false,"given":"Eric C.","family":"Strain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2020.108147_bib0005","article-title":"2020. Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine\/Naloxone","author":"Antoine","year":"2020","journal-title":"Am J Addict."},{"issue":"5","key":"10.1016\/j.drugalcdep.2020.108147_bib0010","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/add.14522","article-title":"What should Clinicians do as Fentanyl Replaces Heroin?","volume":"14","author":"Bisaga","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2020.108147_bib0015","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.drugpo.2017.05.023","article-title":"Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: a mixed methods study","volume":"46","author":"Carroll","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2020.108147_bib0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drugalcdep.2017.04.004","article-title":"Increases in self-reported fentanyl use among a population entering drug treatment: the need for systematic surveillance of illicitly manufactured opioids","volume":"177","author":"Cicero","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108147_bib0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.12.005","article-title":"Fentanyl: receptor pharmacology, abuse potential, and implications for treatment","volume":"106","author":"Comer","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"7","key":"10.1016\/j.drugalcdep.2020.108147_bib0030","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJMp1615145","article-title":"Addressing the fentanyl threat to public health","volume":"376","author":"Frank","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2020.108147_bib0035","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jamainternmed.2016.4310","article-title":"Counterfeit medications and fentanyl","volume":"176","author":"Green","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.drugalcdep.2020.108147_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2017.10.020","article-title":"Substance use patterns associated with recent exposure to fentanyl among people who inject drugs in Vancouver, Canada: a cross-sectional urine toxicology screening study","volume":"183","author":"Hayashi","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108147_bib0045","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0022-3565(24)38239-4","article-title":"Active transport of fentanyl by the blood-brain barrier","volume":"289","author":"Henthorn","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.drugalcdep.2020.108147_bib0050","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jpba.2004.09.024","article-title":"Determination of fentanyl in human plasma and fentanyl and norfentanyl in human urine using LC\u2013MS\/MS","volume":"37","author":"Huynh","year":"2005","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.drugalcdep.2020.108147_bib0055","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1001\/jama.2018.2844","article-title":"Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016","volume":"319","author":"Jones","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2020.108147_bib0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40262-012-0016-7","article-title":"Pharmacokinetics of non-intravenous formulations of fentanyl","volume":"52","author":"L\u00f6tsch","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drugalcdep.2020.108147_bib0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.addbeh.2017.01.014","article-title":"Prevalence and correlates of fentanyl-contaminated heroin exposure among young adults who use prescription opioids non-medically","volume":"68","author":"Macmadu","year":"2017","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2020.108147_bib0070","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2165\/00003088-198308050-00004","article-title":"Clinical pharmacokinetics of fentanyl and its newer derivatives","volume":"8","author":"Mather","year":"1983","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.drugalcdep.2020.108147_bib0075","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/BF03178274","article-title":"Transdermal fentanyl: pharmacology and toxicology","volume":"5","author":"Nelson","year":"2009","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.drugalcdep.2020.108147_bib0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jsat.2018.10.007","article-title":"Fentanyl exposure among patients seeking opioid treatment","volume":"96","author":"Ochalek","year":"2019","journal-title":"J. Subst. Abuse Treat."},{"issue":"6","key":"10.1016\/j.drugalcdep.2020.108147_bib0085","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/jat\/28.6.422","article-title":"Urine concentrations of fentanyl and Norfentanyl during application of duragesic\u00ae transdermal patches","volume":"28","author":"Poklis","year":"2004","journal-title":"J. Anal. Toxicol."},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108147_bib0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000542-199301000-00007","article-title":"Transdermal fentanyl for Cancer pain repeated dose pharmacokinetics","volume":"78","author":"Portenoy","year":"1993","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108147_bib0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0773.1994.tb01068.x","article-title":"Liposolubility and protein binding of oxycodone in vitro","volume":"74","author":"P\u00f6yhi\u00e4","year":"1994","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.drugalcdep.2020.108147_bib0100","series-title":"Solubility and Related Physicochemical Properties of Narcotic Analgesics","author":"Roy","year":"1988"},{"key":"10.1016\/j.drugalcdep.2020.108147_bib0105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\u201cEverything is not right anymore\u201d: buprenorphine experiences in an era of illicit fentanyl","volume":"74","author":"Silverstein","year":"2019","journal-title":"Int. J. Drug Policy"},{"issue":"4","key":"10.1016\/j.drugalcdep.2020.108147_bib0110","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jvp.12501","article-title":"Pharmacokinetics of fentanyl citrate and norfentanyl in holstein calves and effect of analytical performances on fentanyl parameter estimation","volume":"41","author":"Smith","year":"2018","journal-title":"J. Vet. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.drugalcdep.2020.108147_bib0115","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/FTD.0000000000000029","article-title":"Impact of CYP3A5* 3 on plasma exposure and urinary excretion of fentanyl and Norfentanyl in the early postsurgical period","volume":"36","author":"Tanaka","year":"2014","journal-title":"Ther. Drug Monit."},{"issue":"6","key":"10.1016\/j.drugalcdep.2020.108147_bib0120","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/00000542-198906000-00008","article-title":"Absorption characteristics of transdermally administered fentanyl","volume":"70","author":"Varvel","year":"1989","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/j.drugalcdep.2020.108147_bib0125","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/ADM.0000000000000486","article-title":"Impact of fentanyl use on buprenorphine treatment retention and opioid abstinence","volume":"13","author":"Wakeman","year":"2019","journal-title":"J. Addict. Med."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620303124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620303124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:03:23Z","timestamp":1759827803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871620303124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":25,"alternative-id":["S0376871620303124"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108147","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protracted renal clearance of fentanyl in persons with opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108147"}}